The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | - | - | 622 | 240 |
| Research and development (including amounts with related parties) | - | - | 232,366 | 248,149 |
| Selling, general and administrative (including amounts with related parties) | - | - | 129,620 | 102,708 |
| Impairment of intangible assets | - | - | - | 681 |
| Loss from operations | - | - | -362,250 | -351,298 |
| Other (expense) income, net (including amounts with related parties) | - | - | -221,642 | -65,988 |
| Income tax expense | - | - | -40 | 34 |
| Net loss | -351,472 | -413,645 | -583,852 | -417,320 |
| Change in fair value of warrant liabilities | -49,089 | -19,955 | 47,600 | -13,460 |
| Change in fair value of related-party convertible note | -42,773 | 43,472 | -36,203 | - |
| Non-cash interest expense related to revenue interest liability | 41,229 | 38,004 | - | - |
| Stock-based compensation expense | 36,809 | 34,432 | 49,163 | 40,179 |
| Depreciation and amortization | 15,525 | 17,554 | 18,512 | 18,260 |
| Loss on equity method investment | 14,018 | 0 | 0 | 1,333 |
| Change in fair value of derivative liabilities | -6,398 | -13,477 | - | - |
| Non-cash interest items, net (including amounts with related parties) | - | - | 9,189 | - |
| Non-cash lease expense related to operating lease right-of-use assets-Nonrelated Party | 3,502 | - | - | - |
| Non-cash lease expense related to operating lease right-of-use assets | - | 5,756 | 6,112 | 5,932 |
| Non-cash lease expense related to operating lease right-of-use assets-Related Party | 2,754 | - | - | - |
| Non-cash interest items, net (including amounts with related parties) | 2,745 | 1,489 | 137 | -1,318 |
| Transaction costs allocated to warrant liabilities | 2,167 | 0 | 2,010 | 1,082 |
| Non-cash interest items, net (including amounts with related parties) | - | - | - | -11,746 |
| Non-cash interest items, net | 250 | -1,150 | - | - |
| Amortization of related-party notes discounts | 0 | 22,587 | 42,396 | 16,282 |
| Unrealized losses on equity securities | 0 | -632 | -1,591 | -4,190 |
| Unrealized loss on non-marketable equity investment | - | - | - | 0 |
| Deferred tax | - | - | - | -4 |
| Impairment of intangible assets | 0 | 0 | 886 | 681 |
| Loss due to write-off of fixed assets | 570 | 109 | -407 | 273 |
| Accounts receivable | 40,211 | 2,360 | - | - |
| Inventories | 6,325 | 8,272 | - | - |
| Prepaid expenses and other current assets-Nonrelated Party | 7,068 | - | - | - |
| Prepaid expenses and other current assets | - | -1,703 | -5,958 | 16,557 |
| Prepaid expenses and other current assets-Related Party | -2,211 | - | - | - |
| Other assets | -803 | 1,108 | -1,913 | -1,998 |
| Accounts payable | -190 | -3,167 | -6,476 | 8,000 |
| Accrued expenses and other liabilities | 3,184 | -1,508 | 6,689 | 4,102 |
| Due to and due from related parties, net | 477 | 763 | -1,129 | -1,225 |
| Operating lease liabilities-Nonrelated Party | -3,749 | - | - | - |
| Purchase of intangible assets | - | 0 | 0 | 21,229 |
| Operating lease liabilities | - | -5,473 | -2,978 | -4,319 |
| Operating lease liabilities-Related Party | -3,461 | - | - | - |
| Proceeds from sales of property, plant and equipment | - | - | 0 | 0 |
| Net cash used in operating activities | -304,936 | -391,236 | -366,757 | -337,509 |
| Purchases of marketable debt securities, available-for-sale | 241,373 | 140,218 | 10,358 | 34,312 |
| Proceeds from maturities of marketable debt securities, available-for-sale | 64,897 | 115,586 | 10,100 | 128,188 |
| Proceeds from sales of marketable debt securities, available-for-sale | 30,927 | 21,021 | 372 | 33,812 |
| Purchases of property, plant and equipment | 3,846 | 6,888 | 30,584 | 78,162 |
| Software development costs | 406 | - | - | - |
| Acquisition of a business, net of transaction costs | 0 | 1,000 | - | - |
| Investment in joint venture an equity method investment | - | 0 | 0 | 1,000 |
| Cash paid for other investments | 0 | 747 | - | - |
| Proceeds from equity offerings, net of discounts and issuance costs | - | - | - | 60,427 |
| Net cash used in investing activities | -149,801 | -12,246 | -30,470 | 27,297 |
| Proceeds from exercises of stock options | - | - | 294 | 74 |
| Proceeds from equity offerings, net of discounts and issuance costs-Private Placement And At The Market Offerings | 400,562 | 111,357 | 100,561 | - |
| Sale of assets to an entity under common control | - | - | 0 | 0 |
| Proceeds from short-term borrowings | 2,884 | - | - | - |
| Net share settlement for rsus vesting | 2,265 | 5,465 | 3,443 | 616 |
| Principal payments on premium financing | 1,132 | - | - | - |
| Proceeds from exercise of oberland stock option, net of commissions-Options Excluding Stock Purchase And Option Agreement | 220 | 715 | - | - |
| Principal payments of finance leases | 28 | 64 | 77 | 58 |
| Proceeds from second payment, net of issuance costs | 0 | 96,956 | 192,764 | - |
| Proceeds from exercises of warrants | 0 | 73,281 | - | - |
| Proceeds from exercise of oberland stock option, net of commissions-Stock Purchase And Option Agreement | 0 | 4,850 | - | - |
| Proceeds from issuance of related-party promissory notes, net of issuance costs paid | 0 | 0 | 258,700 | 174,125 |
| Proceeds from equity offerings, net of discounts and issuance costs-Stock Purchase And Option Agreement | 0 | 0 | 9,542 | - |
| Payment for contingent consideration | - | 0 | 0 | 339 |
| Net cash provided by financing activities | 400,241 | 281,630 | 558,341 | 233,613 |
| Effect of exchange rate changes on cash and cash equivalents, and restricted cash | 15 | -23 | -292 | 284 |
| Net change in cash and cash equivalents, and restricted cash | -54,481 | -121,875 | 160,822 | -76,315 |
| Cash and cash equivalents, and restricted cash, beginning of year | 143,912 | 265,787 | 104,965 | 181,280 |
| Cash and cash equivalents, and restricted cash, end of year | 89,431 | 143,912 | 265,787 | 104,965 |
ImmunityBio, Inc. (IBRX)
ImmunityBio, Inc. (IBRX)